Mark Molitch is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
680 N Lake Shore Dr
Suite 1000
Chicago, IL 606114546
Telephone
312-695-9797Registry record last updated 8 Jul 2007.
Clinical trials
- Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
Sponsor: Northwestern University
- Study of Glycemic Control on Liver Transplantation Outcomes
Sponsor: Northwestern University
- PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Chiesi USA, Inc.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Corcept TherapeuticsProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
74.8%Insulin Analog63.9%Lantus30%Lantus Solostar24%Humalog17%Novolog Flexpen15%Humalog Kwikpen U-10015%Part D<11 patientsGLP-1 receptor agonist10.9%Victoza 3-Pak100%Part D<11 patientsSensory organs
12.6%Corticosteroid12.6%Hydrocortisone100%Part D<11 patientsHormonal (systemic)
12.6%l-Thyroxine12.6%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1986–2018 per NIH RePORTER. The latest:
- 10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project
Northwestern University at Chicago
FY2018$391,248U01DK048380 - 10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project
Northwestern University at Chicago
FY2017$324,075U01DK048380 - 10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project
Northwestern University at Chicago
FY2016$233,941U01DK048380
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”